Altamira Therapeutics Ltd...

NASDAQ: EARS · Real-Time Price · USD
3.04
-0.06 (-1.94%)
At close: Jul 26, 2021, 6:00 AM

Altamira Therapeutics Income Statement

Financials in CHF. Fiscal year is undefined.
Fiscal Year FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a 305.62K 63.88K
Cost of Revenue
n/a 1.44M 2.24M
Gross Profit
n/a -1.14M -2.18M
Operating Income
-5.92M -18.01M -5.34M
Interest Income
730.2K 114.27K 26.99K
Pretax Income
-7.27M -18.66M -6.81M
Net Income
-7.27M -26.53M -17.06M
Selling & General & Admin
3.12M 3.39M 3.62M
Research & Development
3.04M 14.62M 3.2M
Other Expenses
n/a 112.67K 30.43K
Operating Expenses
6.54M 18.01M 6.87M
Interest Expense
n/a 911.87K 14.11K
Selling & Marketing Expenses
15.35K 15.73K 39.92K
Cost & Expenses
6.54M 18.01M 6.87M
Income Tax Expense
n/a -10.33K -117.94K
Shares Outstanding (Basic)
491K 45.54K 33.12K
Shares Outstanding (Diluted)
491.26K 45.54K 33.12K
EPS (Basic)
-14.81 -582.58 -515.11
EPS (Diluted)
-14.8 -582.58 -515.11
EBITDA
-1.35M -17.64M -6.72M
EBIT
n/a -17.75M -6.79M
Depreciation & Amortization
5.92M 118.89K 76.36K